ENLV vs. NRXP, THTX, APRE, ACST, ACXP, DARE, UBX, LPCN, BIOR, and VIRX
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include NRx Pharmaceuticals (NRXP), Theratechnologies (THTX), Aprea Therapeutics (APRE), Acasti Pharma (ACST), Acurx Pharmaceuticals (ACXP), Daré Bioscience (DARE), Unity Biotechnology (UBX), Lipocine (LPCN), Biora Therapeutics (BIOR), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical preparations" industry.
NRx Pharmaceuticals (NASDAQ:NRXP) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
In the previous week, NRx Pharmaceuticals had 5 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 7 mentions for NRx Pharmaceuticals and 2 mentions for Enlivex Therapeutics. NRx Pharmaceuticals' average media sentiment score of 1.43 beat Enlivex Therapeutics' score of 0.61 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.
4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 21.1% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Enlivex Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
NRx Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
Enlivex Therapeutics received 42 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 77.78% of users gave Enlivex Therapeutics an outperform vote.
Enlivex Therapeutics has a consensus target price of $7.00, indicating a potential upside of 366.67%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than NRx Pharmaceuticals.
Enlivex Therapeutics' return on equity of 0.00% beat NRx Pharmaceuticals' return on equity.
Summary
Enlivex Therapeutics beats NRx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
